A Phase 2 interventional study of Infigratinib is provided as a single dose of minitablets for oral administration and Infigratinib is provided as sprinkle capsules for daily oral administration in Achondroplasia, sponsored by QED Therapeutics, a BridgeBio company. Recruiting at 12 sites in 7 countries. Open to participants aged 0 Years to 32 Months. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by QED Therapeutics, a BridgeBio company (part of BridgeBio) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Achondroplasia with a site in United States — 8 open to participants now, 11 under way, 3 of them phase 3. Achondroplasia · United States.
Among the 29 studies in Achondroplasia with a site in United States, this one is the 10th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 5 of the 10 other live ones, and was the 28th registered.
47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.
Browse Achondroplasia studies →8 of the 29 studies in Achondroplasia with a site in United States are open now. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States, Australia, Canada and 6 more countries
Ages 2–17
Tyra Biosciences, Inc · Sites in United States, Australia, Canada and 5 more countries
Ages 3–10
Ascendis Pharma A/S · Sites in United States, Australia, Austria and 12 more countries
Ages 0–2
BioMarin Pharmaceutical · Sites in United States
Ages 0 mo–18 yrs
Johns Hopkins University · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 0 Years to 32 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 6
First in 1996; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 77 is close to the median of 74 across 28 interventional studies indexed under Achondroplasia.
Median enrollment 76 across the 20 interventional studies, 271 across the 9 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 29 have an industry lead sponsor. The 9 most frequent:
This study is registered under QED Therapeutics, a BridgeBio company, one of the names counted as BridgeBio. Under that name alone:
QED Therapeutics, a BridgeBio company is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
BridgeBio has 5 studies filed under Achondroplasia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Achondroplasia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants \< 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Phase 2b portion, based on safety and PK. The purpose of the Phase 2b, placebo-controlled portion is to evaluate the safety and efficacy of infigratinib in children \< 3 years old with ACH at the selected dose.
PROPEL Infant \& Toddler (I\&T) is a Phase 2, multicenter, randomized, placebo-controlled study that comprises 4 portions: the single ascending dose (SAD) portion (open-label), the Phase 2 portion (open-label), the Phase 2b portion (placebo-controlled), and an Extension Portion (open-label). The study will evaluate children with ACH \< 3 years old being administered oral infigratinib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Ascending Dose Escalation and PK Portion
Drug: Infigratinib is provided as a single dose of minitablets for oral administration
Single Ascending Dose Escalation and PK Portion
Drug: Infigratinib is provided as a single dose of minitablets for oral administration
Single Ascending Dose Escalation and PK Portion
Drug: Infigratinib is provided as a single dose of minitablets for oral administration
Single Ascending Dose Escalation and PK Portion
Drug: Infigratinib is provided as a single dose of minitablets for oral administration
Open-label Safety and PK Portion
Drug: Infigratinib is provided as sprinkle capsules for daily oral administration
Open-label Safety and PK Portion
Drug: Infigratinib is provided as sprinkle capsules for daily oral administration
Open-label Safety and PK Portion
Drug: Infigratinib is provided as sprinkle capsules for daily oral administration
Open-label Safety and PK Portion
Drug: Infigratinib is provided as sprinkle capsules for daily oral administration
Randomized Safety and Efficacy Portion
Drug: Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Randomized Safety and Efficacy Portion
Drug: Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Randomized Safety and Efficacy Portion
Drug: Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Open-label extension portion continuing to assess safety and efficacy in children until they reach 3 years old (+6 months)
Drug: Infigratinib is provided as sprinkle capsules for daily oral administration
Randomized Safety and Efficacy study
Drug: Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Randomized Safety and Efficacy study
Drug: Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Randomized Safety and Efficacy study
Drug: Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
* The initial cohort dose of infigratinib will begin at the protocol-specified starting dose, with subsequent cohort escalation based on protocol specific criteria. * The dose and number of minitablets will be calculated based on individual participant age and weight.
* The cohort dose of infigratinib will be the dose identified in the Single Ascending Dose portion for the age group. * The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months.
* The cohort dose of infigratinib or placebo will be the dose confirmed in the Phase 2 portion for the age group. * The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months.
* The dose of infigratinib will be the dose confirmed in the Phase 2 portion and used in the Phase 2b portion for the age group. * The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months for the first year and every 6 months thereafter.
Single Ascending Dose Portion: Identify the dose of infigratinib to be used in each age cohort of the Phase 2 potion of the study (by assessing safety and PK of infigratinib and its active metabolites)
Time frame: 2 weeks
Phase 2 Portion: Confirm the doses to be used in each age cohort in the Phase 2b portion of the study (by assessing safety and PK of infigratinib and its active metabolites).
Time frame: 52 weeks
Phase 2b Portion: Evaluate the safety and efficacy of infigratinib in infants and children < 3 years old with ACH (by assessing AE's & SAE's)
Time frame: 52 weeks
Extension Portion: Evaluate the safety and efficacy of infigratinib in participants who completed the Phase 2 or Phase 2b portion of the study until they have reached 3 years old (+6 months) (by assessing AE's and SAE's)
Time frame: 3 years and 6 months
Phase 2: Evaluate the safety of oral daily doses of infigratinib (by assessing AEs and SAEs)
Time frame: 52 weeks
Phase 2: Evaluate changes in indicators of growth (by assessing change from BL in body length z-score at Week 52 in relation to ACH tables)
Time frame: 52 weeks
Phase 2: Evaluate changes in indicators of body proportions (by assessing change from BL to Week 52 in upper-to-lower body segment ratio and head circumference/body length ratio)
Time frame: 52 weeks
Phase 2: Change from BL in Health-related Quality of Life (HRQoL) (as assessed by Infant and Toddler Quality of Life Inventory [ITQoL] tool)
Time frame: 52 weeks
Phase 2: Milestone Development of motor skills (assessed with development milestone charts)
Time frame: 52 weeks
Phase 2: Milestone Development of language skills (assessed with development milestone charts)
Time frame: 52 weeks
Phase 2: Milestone Development of personal-social skills (assessed with development milestone charts)
Time frame: 52 weeks
Phase 2: Skull and brain morphology (as assessed using MRI)
Time frame: 52 weeks
Phase 2: Age at closure of cranial structures (as assessed by physical examination)
Time frame: 52 weeks
Phase 2: Age at closure of fontanelles (as assessed by physical examination)
Time frame: 52 weeks
Phase 2: Incidence of surgical interventions (i.e., cervical decompression, adenotonsillectomy etc)
Time frame: 52 weeks
Phase 2: Incidence and severity of sleep apnea (as assessed by polysomnography)
Time frame: 52 weeks
Phase 2: Bone morphology (as assessed using x-rays)
Time frame: 52 weeks
Phase 2b: Evaluate the pharmacokinetic (PK) profile of infigratinib and its metabolites (by assessing the PK of infigratinib and its active metabolites)
Time frame: 52 weeks
Phase 2b: Change from BL in Health-related Quality of Life (HRQoL) (as assessed by Infant and Toddler Quality of Life Inventory [ITQoL] tool)
Time frame: 52 weeks
Phase 2b: Evaluate the safety of oral daily doses of infigratinib (by assessing AEs and SAEs)
Time frame: 52 weeks
Phase 2b: Evaluate changes in indicators of growth (by assessing change from BL in body length z-score at Week 52 in relation to ACH tables)
Time frame: 52 weeks
Phase 2b: Evaluate changes in indicators of growth (by assessing AHV at Week 52 in relation to ACH tables)
Time frame: 52 weeks
Phase 2b: Evaluate changes in indicators of growth (by assessing AHV Z-score at Week 52 in relation to ACH tables)
Time frame: 52 weeks
Phase 2b: Evaluate changes in indicators of body proportions (by assessing change from BL to Week 52 in upper-to-lower body segment ratio and head circumference/body length ratio)
Time frame: 52 weeks
Phase 2b: Evaluate changes in indicators of growth (by assessing change from BL in Weight-for-Length Z-score at Week 52)
Time frame: 52 weeks
Phase 2b: Milestone Development of motor skills (assessed with development milestone charts)
Time frame: 52 weeks
Phase 2b: Milestone development of language skills (assessed with development milestone charts)
Time frame: 52 weeks
Phase 2b: Milestone development of personal-social skills (assessed with development milestone charts)
Time frame: 52 weeks
Phase 2b: Skull and brain morphology (as assessed using MRI)
Time frame: 52 weeks
Phase 2b: Age at closure of cranial structures (as assessed by physical examination)
Time frame: 52 weeks
Phase 2b: Age at closure of fontanelles (as assessed by physical examination)
Time frame: 52 weeks
Phase 2b: Incidence of surgical interventions (i.e., cervical decompression, adenotonsillectomy etc)
Time frame: 52 weeks
Phase 2b: Incidence and severity of sleep apnea (as assessed by polysomnography)
Time frame: 52 weeks
Phase 2b: Bone morphology (as assessed using x-rays)
Time frame: 52 weeks
Extension Phase: Evaluate the safety of oral daily doses of infigratinib (by assessing AEs and SAEs)
Time frame: Until they have reached 3 years old (+6 months)
Extension Phase: Change from BL in body length Z-score
Time frame: Until they have reached 3 years old (+6 months)
Extension Phase: Change from BL in upper to lower body segment ratio (cm)
Time frame: Until they have reached 3 years old (+6 months)
Extension Phase: Change from BL in head circumference body length ratio
Time frame: Until they have reached 3 years old (+6 months)
Extension Phase: Milestone development of social/emotional skills (assessed with development milestone charts)
Time frame: Until they have reached 3 years old (+6 months)
Extension Phase: Milestone development of language communication skills (assessed with development milestone charts)
Time frame: Until they have reached 3 years old (+6 months)
Extension Phase: Milestone development of cognitive skills (assessed with development milestone charts)
Time frame: Until they have reached 3 years old (+6 months)
Extension Phase: Milestone development of movement/physical development skills (assessed with development milestone charts)
Time frame: Until they have reached 3 years old (+6 months)
Extension Phase: Age at closure of cranial structures (as assessed by physical examination)
Time frame: Until they have reached 3 years old (+6 months)
Extension Phase: Age at closure of fontanelles (as assessed by physical examination)
Time frame: Until they have reached 3 years old (+6 months)
Extension Phase: Incidence of surgical interventions (i.e., cervical decompression, adenotonsillectomy etc)
Time frame: Until they have reached 3 years old (+6 months)
Extension Phase: Bone morphology (as assessed using x-rays)
Time frame: Until they have reached 3 years old (+6 months)
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Mar 2030, 52 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
QED Therapeutics, a BridgeBio company →